Figure 7.

Depletion of B cells eliminates the improved response to anti-PD1/anti-CTLA4 therapy in A12-KO T11 tumors. BALB/c mice were orthotopically injected with A12-KO T11 cells and then either treated with anti-PD1/anti-CTLA4 therapy, as in Figure 6, or untreated. Three days prior to administration of anti-PD1/anti-CTLA4 treatment, mice received tail vein injections of anti-CD20 depleting or isotope control antibodies. (a) Representative FACS analysis of splenic B cells seven days after tail vein injections. (b, c) The effect of anti-PD1/anti-CTLA4 antibodies on tumor growth rates (left) and progression-free survival rates (right) in mice with A12-KO (g1) tumors (b) and A12-KO (g2) tumors (c). Progression was defined as a 20% increase in tumor diameter, or 1.44-fold increase in tumor area.